+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07190469

Phase 1 Study of PQ203 Given Weekly by IV to Patients With Advanced Solid Tumors Including Triple Negative Breast Cancer to Evaluate Safety and Determine Recommended Dose

Led by ProteinQure Inc. · Updated on 2026-02-23

80

Participants Needed

4

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating PQ203, a peptide drug-conjugate, in patients with advanced solid tumors including triple negative breast cancer TNBC. This open-label, first-in-human study aims to determine the safety and tolerability of PQ203, establish a recommended Phase 2 dose, and assess its pharmacokinetics and preliminary antitumor activity. The study includes patients whose cancer has progressed despite standard treatments or who cannot receive approved therapies. PQ203 is given as a once-weekly intravenous infusion. The study has two parts Phase 1A includes dose escalation and expansion to find the recommended dose and evaluate safety in selected tumor types. Phase 1B further assesses this dose to better understand safety, drug levels in the body, and early signs of effectiveness. All participants receive PQ203, and the study plans up to seven ascending dose groups. Participants will be closely monitored from the time of informed consent until about 28 days after the last dose. Assessments include tracking treatment-related side effects, measuring tumor response, and evaluating how the drug moves and acts in the body. Laboratory tests will assess organ function before dosing. Safety, tolerability, and preliminary antitumor effects are the main outcomes. The study may continue up to early 2029.

CONDITIONS

Brief Title

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here